We have previously shown that obese patients with NAFLD, and particularly those with advanced hepatic fibrosis, frequently develop metabolic hyperendotoxemia, which is associated with a reduction in the phagocytic capacity of KCs and more severe inflammation and oxidative stress (Shida et al., 2018). This evidence concerns the gene TBCE and metabolic dysfunction-associated steatotic liver disease.